Overall rank by patents
#28,684
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Eliaz Therapeutics, Inc.
USPTO PatentsView assignee record - 9 granted patents across 5 technology areas, active 2017–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).
9
Total patents granted
5
CPC technology areas
8.0
Avg claims per patent
+250%
5-year filing velocity
The verdict
Eliaz holds 9 US patents across 5 technology areas, rank #28,684 of 50,000 tracked assignees.
- #28,684
- of 50,000 US assignees by volume
- Top 77%
- by Innovation Score (27.3/100)
- 8.0
- avg claims per patent
- +250%
- filing velocity, last 5 yrs
Portfolio overview
Eliaz Therapeutics, Inc. has been granted 9 US utility patents between 2017 and 2024, placing Eliaz Therapeutics, Inc. at rank #28,684 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 8.0 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a US Corporation, Eliaz Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Eliaz sits between Electrosea, Llc (9 patents, rank #28,680) and Elopak Systems Ag (9 patents, rank #28,688) - the closest US assignees by grant volume. The composite Innovation Score of 27.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 7 grants, compared with 2 in the 2015–2019 window, a +250% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Eliaz Therapeutics, Inc.'s 8.0 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Eliaz Therapeutics, Inc. against peers pursuing similar technology classes.
Who files at Eliaz's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Electrosea
ElectroSea, LLC
9 patents
- Electrolux Consum…
Electrolux Consumer Products, Inc.
9 patents
- Elekta Instrument…
Elekta Instrument AB
9 patents
- Elektrofi
Elektrofi, Inc.
9 patents
- Elijah Tooling
Elijah Tooling, Inc.
9 patents
- Ellergon Antriebs…
Ellergon Antriebstechnik Gesellschaft m.b.H.
9 patents
- Elli & Nooli
Elli & Nooli, LLC
9 patents
- Elopak Systems
Elopak Systems AG
9 patents
- Eliaz Therapeutics ◀
Eliaz Therapeutics, Inc.
9 patents
What this shows Eliaz holds 9 patents at rank #28,684, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Eliaz
By rank, the assignees closest to #28,684 in granted patent volume.
- Electrosea, Llc #28,680 · 9 patents
- Electrolux Consumer Products, Inc. #28,681 · 9 patents
- Elekta Instrument AB #28,682 · 9 patents
- Elektrofi, Inc. #28,683 · 9 patents
- Elijah Tooling, Inc. #28,685 · 9 patents
- Ellergon Antriebstechnik Gesellschaft M.b.h. #28,686 · 9 patents
- Elli & Nooli, Llc #28,687 · 9 patents
- Elopak Systems Ag #28,688 · 9 patents
Leaders in A61M (Devices FOR Introducing Media INTO)
Other assignees with the most granted patents in Eliaz's primary technology class.
- Becton, Dickinson And Company 1,249 in class
- Sanofi-aventis Deutschland Gmbh 1,159 in class
- Boston Scientific Scimed, Inc. 901 in class
- Koniniklijke Philips N.v. 836 in class
- Fisher & Paykel Healthcare Limited 773 in class
- Covidien Lp 726 in class
- Terumo Kabushiki Kaisha 724 in class
- Resmed Pty Ltd 682 in class
Eliaz's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
27 Top 77% higher than 23% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 11.1% |
| 2019 | 1 | 11.1% |
| 2020 | 1 | 11.1% |
| 2021 | 2 | 22.2% |
| 2022 | 3 | 33.3% |
| 2024 | 1 | 11.1% |
Which technologies does Eliaz Therapeutics, Inc. patent most?
Top 5 of 5 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Simple
Velocity Accelerating
Frequently Asked Questions
How many patents does Eliaz Therapeutics, Inc. hold?
Eliaz Therapeutics, Inc. holds 9 US granted patents filed between 2017 and 2024, spanning 5 technology areas.
What is Eliaz Therapeutics, Inc.'s Innovation Score?
Eliaz Therapeutics, Inc. has an Innovation Score of 27.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Eliaz Therapeutics, Inc. focus on?
Eliaz Therapeutics, Inc.'s top technology area is A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR) with 9 patents. The company has filed patents in 5 CPC subclasses total.
Is Eliaz Therapeutics, Inc.'s patent filing rate increasing or decreasing?
Eliaz Therapeutics, Inc.'s recent filing velocity is +250% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Eliaz Therapeutics, Inc.'s patents?
Eliaz Therapeutics, Inc.'s patents average 8.0 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Eliaz Therapeutics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Eliaz's 9 grants land it in the top 77% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Eliaz ranks #28,684 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61M - see who else leads that technology area. A61M leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.